United Therapeutics will report phase 3 and registry data at CHEST 2026 indicating that ralinepag reduced clinical worsening risk in pulmonary arterial hypertension irrespective of baseline noninvasive risk status, and that nebulized treprostinil lowered disease progression events in idiopathic pulmonary fibrosis. Interim data from the PHINDER and DeciPHer-ILD studies point to elevated mortality risk scores and advanced hemodynamic compromise in interstitial lung disease patients at the time of detection. Both agents remain investigational for these indications, with FDA applications under review.
Key Points
- Ralinepag cut clinical worsening risk across baseline risk strata in PAH
- Nebulized treprostinil reduced disease progression events in idiopathic pulmonary fibrosis
- Registry data support earlier pulmonary hypertension screening in interstitial lung disease
Longevity Analysis
Pulmonary vascular disease is typically identified only after gas exchange and right heart function have already deteriorated, which is precisely why registry findings showing advanced hemodynamics and impaired exercise capacity at enrollment carry weight. Shifting detection earlier — using validated mortality risk models rather than waiting for symptomatic decline — reframes screening as signal interpretation rather than late-stage confirmation. The interdependence here is direct: compromised oxygen delivery constrains circulation, energy production, and functional capacity simultaneously, so intervening before the right ventricle remodels preserves far more than lung mechanics.
Original published by LT Wire.